Structure Therapeutics (GPCR) Accumulated Expenses (2022 - 2026)

Structure Therapeutics' Accumulated Expenses history runs 5 years deep, the most recent figure standing at $6.4 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 34.03% year-over-year to $6.4 million; the TTM figure through Mar 2026 stood at $6.4 million (up 34.03% YoY), while the FY2025 annual figure was $46.5 million, up 538.45% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $6.4 million, down from $46.5 million in the prior quarter.
• The five-year high for Accumulated Expenses was $46.5 million in Q4 2025, with the low at $1.1 million in Q1 2023.
• The 5-year median for Accumulated Expenses is $6.6 million (2022), against an average of $12.8 million.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses surged 1247.99% in 2024, then plunged 70.3% in 2025.
• Structure Therapeutics' Accumulated Expenses stood at $6.7 million in 2022, then jumped by 175.3% to $18.6 million in 2023, then sank by 60.72% to $7.3 million in 2024, then surged by 538.45% to $46.5 million in 2025, then sank by 86.32% to $6.4 million in 2026.
• Business Quant data shows GPCR's Accumulated Expenses at $6.4 million in Q1 2026, $46.5 million in Q4 2025, and $36.9 million in Q3 2025.